The small molecule 4EGI-1 was identified as an inhibitor of cap-dependent translation initiation owing to its disruption of the eIF4E/eIF4G association through binding to eIF4E. 4EGI-1 exhibits growth-inhibitory and apoptosisinducing activity in cancer cells; thus, we were interested in its therapeutic 
Introduction
Protein translational control is an important strategy by which eukaryotic cells regulate gene expression. A prime target of translational control is eukaryotic translation initiation factor 4E (eIF4E), which recognizes and binds to the 7-methylguanosine cap structure present at the 5′ untranslated regions of cellular messenger RNA (mRNA) and delivers these mRNA to the eIF4F translation initiation complex, which is composed of the cap-binding protein eIF4E, the RNA helicase eIF4A, and the scaffolding protein eIF4G [1, 2] .
Assembly of the eIF4F complex is dependent on eIF4E availability. Given that eIF4E is the least abundant among the initiator factors involved in the eIF4F complex, eIF4E is the rate-limiting factor for cap-dependent translation initiation [2] . Consequently, changes in eIF4E levels profoundly affect translation rates of certain proteins, particularly those related to cell growth and survival involved in oncogenesis (e.g., c-Myc, vascular endothelial growth factor, ODC, cyclin D1, hypoxia-inducing factor-1 [HIF-1], andMcl-1), which, under normal cellular conditions, are translationally repressed [3, 4] .
Under normal cellular conditions, eIF4E is bound by the inhibitory 4E-BPs, which sequester eIF4E from interaction with eIF4G, preventing the formation of the eIF4F translation initiation complex. The activities of 4E-BPs are regulated by phosphorylation through themammalian target of rapamycin (mTOR) pathway. Hypophosphorylated 4E-BPs sequester eIF4E, inhibiting translation, whereas hyperphosphorylated 4E-BPs do not bind eIF4E and the eIF4E is free to participate in translation initiation. The 4E-BPs compete with eIF4G for binding to eIF4E because they share the same binding motif on eIF4E [5] [6] [7] .
Abnormal regulation of cellular eIF4F caused by elevated levels of initiation factors or dysregulation of 4E-BP phosphorylation plays an important role in oncogenesis. eIF4E expression is frequently elevated in many types of cancers and is associated with malignant progression [5, 8] . Enforced overexpression of eIF4E in experimental systems induces cell transformation and tumorigenesis both in cell cultures and in animal models [4, [9] [10] [11] [12] .
Similar results were also observed when eIF4G was overexpressed [13] .
Conversely, ectopic expression of 4EBPs can partially revert eIF4E-transformed cells to a nonmalignant phenotype [14] and induce apoptosis in cells transformed by other oncogenes such as Ras [9, 15] . Thus, the eIF4F complex and eIF4E are considered to be promising cancer therapeutic targets. Accordingly, eIF4E-specific antisense oligonucleotides have been shown to effectively repress the expression of eIF4E-regulated proteins (e.g., vascular endothelial growth factor, cyclin D1, survivin, c-Myc, Bcl-2), induce apoptosis, inhibit tumor growth in vivo with minimal toxicity, and are now being tested in phase 1 clinical trials [16] . Several rapamycin analogs, which decrease eIF4F levels by inhibiting mTOR-dependent 4E-BP phosphorylation, have antitumor activity and have been approved for cancer treatment or are being evaluated as cancer drugs in clinical trials [17] [18] [19] .
The death ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which induces apoptosis on binding to its receptors death receptors 4 and 5 (DR4 and DR5), has recently received much attention because it preferentially induces apoptosis in transformed or malignant cells but not in most normal cells [20] . Currently, recombinant human TRAIL is being tested as an anticancer agent in phase 1 clinical trials [21] . In addition, agonistic antibodies against DR4 and DR5, which directly activate the extrinsic apoptotic pathway, have been developed and tested in phase 1 or 2 trials and found to be well tolerated [22, 23] . Thus, death receptor-mediated apoptosis, particularly TRAIL death receptor-mediated apoptosis, has been subject to intense research as a cancer therapeutic target [23, 24] . However, an important issue in this regard is the intrinsic resistance of certain cancer cells to TRAIL/death receptor-induced apoptosis [25] . Fortunately, certain cancer therapeutic agents can sensitize various types of cancer cells to TRAIL-induced apoptosis or overcome the intrinsic apoptotic resistance to TRAIL [26] . Accordingly, these agents are potentially useful in combination with TRAIL or TRAIL receptor agonistic antibodies to enhance TRAIL-or TRAIL receptor-based cancer therapy. TRAIL/death receptor-mediated apoptosis is primarily inhibited by cellular FLICE-inhibitory protein (c-FLIP), which inhibits caspase-8 activation by preventing recruitment of caspase-8 to the death-inducing signaling complex called DISC [27, 28] . c-FLIP has multiple splice variants, however, only two of them (i.e., FLIP L and FLIP S ) have been well characterized at the protein levels [29, 30] . The levels of c-FLIP, including both FLIP L and FLIP S , are subject to regulation by ubiquitin/proteasome-mediated degradation [31] [32] [33] . It has been well documented that elevated c-FLIP expression protects cells from death receptor-mediated apoptosis, whereas down-regulation of c-FLIP by chemicals or small interfering RNA (siRNA) sensitizes cells to death receptor-mediated apoptosis [29] . Moreover, overexpression of c-FLIP also protects cells from apoptosis induced by cancer therapeutic agents such as etoposide and cisplatin [34] [35] [36] [37] [38] .
The small molecule, 4EGI-1, has been identified through highthroughput screens of compound libraries to bind eIF4E and disrupt eIF4E/eIF4G association. This compound selectively inhibits capdependent translation and exhibits activity against multiple cancer cell lines including induction of apoptosis [39] . We are interested in its therapeutic activity in lung cancer.
Moreover, we are particularly interested in identifying small molecules that can sensitize cancer cells to TRAIL-induced apoptosis. Interestingly, we found that 4EGI-1 alone not only induced apoptosis of human lung cancer but also cooperated with TRAIL in augmenting apoptosis. Thus, we focused our study on revealing the mechanisms by which 4EGI-1 enhances TRAILinduced apoptosis and the role of cap-dependent translation in this process. 
Materials and Methods

Reagents
Cell Lines and Cell Culture
Human non-small cell lung cancer cell lines used in this study were purchased from the American Type Culture Collection (Manassas, VA). The H157-Lac Z-5, H157-FLIP L -21 and H157-FLIP S -1 stable transfectants that express control Lac Z, ectopic FLIP L , and ectopic FLIP S , respectively, were described previously [40] . These cell lines were cultured in RPMI 1640 containing 5% fetal bovine serum at 37°C in a humidified atmosphere of 5% CO 2 and 95% air.
Cell Survival Assay
Cells were seeded in 96-well cell culture plates and treated the next day with the agents indicated. The viable cell number was determined using the sulforhodamine B (SRB) assay, as previously described [41] .
Detection of Apoptosis
Apoptosis was evaluated by Annexin V staining using Annexin V-PE apoptosis detection kit purchased from BD Biosciences (San Jose, CA) following the manufacturer's instructions. We also detected PARP cleavage by Western blot analysis (as described below) as an additional indicator of apoptosis.
Western Blot Analysis
Whole-cell protein lysates were prepared and analyzed by Western blot analysis as described previously [42, 43] .
Detection of DR5 mRNA
DR5 mRNA levels were detected with reverse transcription-polymerase chain reaction (RT-PCR) as described previously [44] .
7-Methyl GTP Pull-down for Analysis of eIF4F Complex Formation eIF4F complex in cell extracts was detected using affinity chromatography 7-methyl GTP (m 7 GTP)-Sepharose as described previously [45] . Briefly, the given cells were lysed in buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 , 1% Triton X-100, 2.5 mM sodium pyrophosphate, and protease inhibitor cocktail, on ice for 15 minutes. After centrifugation at 12,000g for 15 minutes at 4°C, the supernatants were collected and incubated with m 7 GTPSepharose (GE Healthcare Bio-Sciences, Corp/Amersham, Piscataway, NJ) at 4°C for 2 hours with constant shaking. Beads were washed three times with lysis buffer and three times with 1 x PBS. The samples were then denatured, and the supernatants were then loaded to SDS-PAGE for Western blot analysis.
Immunoprecipitation for Detection of Ubiquitinated c-FLIP
H157-FLIP L -21 cells, which stably express FLIP L , were transfected with HAubiquitin plasmid using the FuGENE 6 transfection reagent (Roche Diagnostics Corp, Indianapolis, IN) following the manufacturer's instructions.
After 24 hours, the cells were treated with 4EGI-1 or MG132 plus 4EGI-1 for the given time and were then lysed for immunoprecipitation of Flag-FLIP L using Flag M2 monoclonal antibody (Sigma) as previously described [46] followed by the detection of ubiquitinated FLIP L with Western blot analysis using anti-HA antibody (Abgent, San Diego, CA).
SiRNA-Mediated Gene Silencing
The siRNA duplexes for nonsilencing control, DR5, and CHOP were described previously [43, 44] . eIF4E siRNA (5′-GGACGAUGGCUAAUUACAUdTdT-3′) was described previously [47] .
Transfection of these siRNA duplexes was conducted in six-well plates using 
Transient Transfection and Luciferase Activity Assay
The reporter constructs harboring different DR5 5′-flanking regions, transient transfection, and luciferase assay were all the same as described previously [44, 48] .
Results
4EGI-1 Inhibits the Growth of Lung Cancer Cells and Cooperates with TRAIL to Augment Apoptosis
We first determined the effects of 4EGI-1 as a single agent on the growth of Collectively, these results indicate that 4EGI-1 cooperates with TRAIL to augment the induction of apoptosis. 
4EGI-1 Modulates DR5 and c-FLIP Levels That Contribute to Cooperative Induction of Apoptosis by the Combination of 4EGI-1 and TRAIL
To determine the mechanism by which 4EGI-1 cooperates with TRAIL to augment apoptosis, we analyzed the modulatory effects of 4EGI-1 on DR4, DR5, and c-FLIP, which are often involved in drug-induced sensitization of TRAIL/death receptor-induced apoptosis [26] . As shown in , 4EGI-1 ncreased DR5 expression and reduced c-FLIP (both FLIP L and FLIP S ) levels n every tested cell line; however, it decreased DR4 expression in these cell Thus, these results clearly indicate that DR5 induction also contributes to cooperative induction of apoptosis by the 4EGI-1 and TRAIL combination. It is likely that DR5 induction is also important for 4EGI-1-induced apoptosis.
4EGI-1 Enhances TRAIL-Induced Apoptosis Independent of Its Inhibitory Effect on Cap-Dependent Protein Translation
Given that 4EGI-1 was developed as an eIF4E/eIF4G interaction inhibitor [39] , we asked whether the effects of 4EGI-1 on DR5 induction, c-FLIP reduction, and enhancement of TRAIL-induced apoptosis are secondary to its inhibition of cap-dependent protein translation. Thus, we first analyzed whether 4EGI-1 inhibits eIF4E and eIF4G interaction or eIF4F complex formation in our cell systems. In an m7GTP pull-down assay, we detected much lower amounts of eIF4G in 4EGI-1-treated cells than in DMSO-treated cells ( ), indicating that 4EGI-1 indeed disrupts the formation of eIF4F complex in our cell systems as reported [39] . Moreover, we examined the effects of 4EGI-1 on the expression of cyclin D1 and HIF-1α, which are known to be regulated through cap-dependent translation initiation mechanisms. As presented in , 4EGI-1 decreased the levels of both cyclin D1 and HIF-1α in concentration-and timedependent manners, suggesting that 4EGI-1 inhibits cap-dependent protein translation.We noted that HIF-1α expression was not detected in A549 and H460 cells; this is likely due to the normoxia condition in our experiment. After these studies, we determined whether knockdown of eIF4E with eIF4E
siRNA can generate similar effects as 4EGI-1 does in inducing DR5
expression, reducing c-FLIP levels and enhancing TRAILinduced apoptosis.
Knockdown of eIF4E effectively decreased cyclin D1 levels but not c-FLIP evels. Interestingly, eIF4E knockdown actually decreased DR5 levels ( Furthermore, we checked the effects of rapamycin, an mTOR inhibitor that is known to inhibit cap-dependent protein translation [49] , on modulation of DR5, c-FLIP and TRAIL-induced apoptosis. Treatment of cells with rapamycin nhibited the phosphorylation of S6, a known readout of mTOR signaling activity, and decreased the levels of cyclin D1 and HIF-1α but did not increase DR5 or reduce c-FLIP levels ( Figure W1A ). Similarly, treatment of cells with rapamycin combined with TRAIL did not show any enhanced effects on decreasing cell survival ( Figure W1B ). Together, these results further our notion that 4EGI-1 cooperates with TRAIL to augment apoptosis independent of inhibition of cap-dependent protein translation.
4EGI-1 Induces DR5 Expression through a CHOP-Dependent Mechanism
To understand how 4EGI-1 upregulates DR5 expression, we then checked whether 4EGI-1 increases DR5 expression at the transcriptional level. By RT-PCR, we detected concentration-dependent increases of DR5 mRNA in cells exposed to 4EGI-1 () Moreover 4EGI-1 increased DR5 promoter activity () Subsequently, we determined whether 4EGI-1 indeed alters CHOP Figure 5A Figure 5B
Figure 5B 
4EGI-1 Downregulates c-FLIP Levels through Ubiquitin/Proteasome-Mediated Degradation
We also determined the mechanism by which 4EGI-1 reduces c-FLIP levels. 
Discussion
In the present study, we have demonstrated that the eIF4E and eIF4G interaction inhibitor 4EGI-1 effectively inhibited the growth of human lung cancer cells and induces apoptosis. These findings are consistent with previous work [39] . Moreover, we have shown that 4EGI-1 cooperates with TRAIL to augment induction of apoptosis in a panel of human lung cancer cells. To the best of our knowledge, this is the first study to show the interaction between 4EGI-1 and TRAIL/death receptor-induced apoptosis. DR4, DR5, and c-FLIP are key components in the TRAIL-mediated apoptotic Figure 6C pathway [23] . Modulation of their expression levels alters cell sensitivity to TRAIL-induced apoptosis [26] . In this study, we found that 4EGI-1 increased DR5 expression and reduced c-FLIP levels inmultiple lung cancer cell lines.
When DR5 induction was blocked by siRNA-mediated knockdown of DR5 expression or ectopic c-FLIP was expressed, the cooperative induction of apoptosis by the 4EGI-1 and TRAIL combination was abrogated ( ).
Thus, we conclude that both DR5 induction and c-FLIP down-regulation are critical events that mediate enhanced induction of apoptosis by the combination of 4EGI-1 and TRAIL.We noted that blockage of DR5 induction or overexpression of ectopic c-FLIP also attenuated apoptosis induced by 4EGI-1 alone ( ), suggesting that DR5 induction and c-FLIP reduction also contribute to 4EGI-1-induced apoptosis. Unexpectedly, we also observed that DR4 expression was reduced by 4EGI-1 ( ). The mechanism underlying the down-regulation of DR4 by 4EGI-1 is unknown;
however, this warrants our further investigation.
A previous study suggested that c-FLIP regulation in glioblastoma multiforme cells involves an mTOR-dependent translational mechanism [52] .
Accordingly, rapamycin inhibited c-FLIP expression and sensitized glioblastoma multiforme cells to TRAIL-induced apoptosis [52] . In this study, 4EGI-1, as an eIF4E and eIF4G interaction inhibitor, disrupted the interaction between eIF4E and eIF4G and inhibited the expression of both cyclin D1 and HIF-1α, both of which are regulated by cap-dependent translation mechanisms, in our cell systems (i.e., lung cancer cells; ), indicating that 4EGI-1, as reported [39] , indeed inhibits eIF4F formation and capdependent protein translation. However, neither eIF4E siRNA (which inhibits eIF4F formation) nor rapamycin (which inhibits mTOR-dependent protein translation) increased DR5 expression, reduced c-FLIP levels or enhanced TRAIL-induced apoptosis in our cell systems, although they did downregulate the levels of cyclin D1 and HIF-1α ( and W1). These data suggest that 4EGI-1 is unlikely to modulate the levels of DR5 and c-FLIP and augment TRAIL-induced apoptosis through inhibition of eIF4F-mediated cap-dependent protein translation. Our data are in agreement with another recent study showing that inhibition of mTOR with either rapamycin or mTOR siRNA failed to enhance TRAIL-induced apoptosis in glioblastoma cells [53] . Thus, we suggest that 4EGI-1 modulates the levels of DR5 and c-FLIP and enhances TRAIL-induced apoptosis independent of inhibition of cap-dependent protein translation, for example, through "off-target" is known to be a typical protein associated with ER stress-induced apoptosis [55] . In addition to CHOP, we also detected increases in ATF4 and p-eIF2a, two other ER stress-associated proteins, in cells treated with 4EGI-1 (
). Thus, it is possible that 4EGI-1 induces ER stress, leading to CHOP-dependent DR5 up-regulation. We noted that CHOP blockage abolished not only DR5 induction but also PARP cleavage by 4EGI-1 ( ), suggesting that CHOP induction is also important for 4EGI-1-induced apoptosis. This furthers our notion that DR5 induction is important for 4EGI-1-induced apoptosis as well.
c-FLIP proteins are known to be regulated by ubiquitin/proteasome-mediated degradation [31] [32] [33] . In this study, we found that 4EGI-1 treatment reduced c- In summary, the current study has revealed a novel biological function of 4EGI-1 that sensitizes human lung cancer cells to TRAIL-induced apoptosis.
Cooperative augmentation of apoptosis by the 4EGI-1 and TRAIL combination involves CHOP-dependent DR5 induction and 
